View Future GrowthChain Bridge I 과거 순이익 실적과거 기준 점검 0/6Chain Bridge I의 수입은 연평균 -34.9%의 비율로 감소해 온 반면, Capital Markets 산업의 수입은 연간 6.1% 증가했습니다.핵심 정보-34.90%순이익 성장률2.94%주당순이익(EPS) 성장률Capital Markets 산업 성장률10.26%매출 성장률n/a자기자본이익률n/a순이익률n/a최근 순이익 업데이트30 Sep 2024최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Apr 02Chain Bridge I announced delayed annual 10-K filingOn 04/01/2026, Chain Bridge I announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Feb 19Chain Bridge I Receives Notice of OTCQB Delisting and Transfer to OTCID Basic MarketAs previously disclosed, on November 12, 2025, Chain Bridge I (the “Company”) received a written notice from the OTC Markets Group (“OTC”) notifying the Company that, because the Company’s public float as it is currently displayed on the Company profile is less than 10% of the total shares outstanding, the Company is not currently in compliance with the public float requirement for continued listing on OTCQB Venture Market (“OTCQB”), as set forth in Section 2 of the OTCQB listing. On February 11, 2026, the Company received a written notice from OTC indicating that the cure period has now expired. Consequently, the Company’s securities were moved from the OTCQB market to the OTCID Basic Market (“OTCID”) on February 12, 2026. OTC further notified the Company that if it would like to be moved back to OTCQB, it must increase public float to at least 10% of the total shares outstanding and meet all of the eligibility requirements under Section 1 of the OTCQB listing standards. The Company will continue to file its periodic reports and remain subject to the reporting obligations under the Securities Exchange Act of 1934. The Company is actively evaluating strategic options to regain compliance with relevant listing standards and remains committed to upholding transparency and stability for all stakeholders.공시 • Sep 09CommLoan, Inc signed a letter of intent to acquire .Chain Bridge I (OTCPK:CBRR.F) in a reverse merger transaction on September 8, 2025.CommLoan, Inc signed a letter of intent to acquire .Chain Bridge I (OTCPK:CBRR.F) in a reverse merger transaction on September 8, 2025. Under the terms of the LOI, CBRRF and CommLoan would become a combined entity, with CommLoan’s existing equity holders rolling 100% of their equity into the combined public company. Upon the closing of the transaction, the combined company will be named CommLoan Inc., and would be led by CommLoan’s founder and CEO, Mitch Ginsberg. The new company’s common stock is expected to be listed on the Nasdaq Capital Market. CBRRF expects to announce additional details regarding the proposed business combination when a definitive agreement is executed, which is expected later in Q4 2025. The transaction is subject to approval by regulatory board, approval of merger agreement by target board, approval of offer by acquirer shareholders, approval of offer by acquirer board, approval of offer by target shareholders, consummation of due diligence investigation and definitive agreement. The expected completion of the transaction is in first half of 2026.공시 • Jun 22Chain Bridge I Auditor Raises 'Going Concern' DoubtChain Bridge I filed its Annual on Jun 20, 2025 for the period ending Dec 31, 2024. In this report its auditor, Russell Bedford Stefanou Mirchandani LLP - RBSM LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.공시 • Apr 02Chain Bridge I announced delayed annual 10-K filingOn 04/01/2025, Chain Bridge I announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Nov 20Chain Bridge I(OTCPK:CBRR.F) dropped from NASDAQ Composite IndexChain Bridge I has been removed from NASDAQ Composite Index.공시 • Nov 15Chain Bridge I announced delayed 10-Q filingOn 11/14/2024, Chain Bridge I announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Nov 13Chain Bridge I to be Delisted from The Nasdaq Stock Market Due to Non-Compliance with Listing Rule IM-5101-2On November 12, 2024, Chain Bridge I (the ‘Company’) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market (‘Nasdaq’) stating that, pursuant to Nasdaq Listing Rule IM-5101-2 (‘Rule IM-5101-2’), the staff of Nasdaq (‘Staff’) had determined that (i) the Company’s securities will be delisted from Nasdaq, (ii) trading of the Company’s Class A common stock and units will be suspended at the opening of business on November 19, 2024 and (iii) a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Company’s securities from listing and registration on Nasdaq. Under Rule IM-5101-2, a special purpose acquisition company must complete one or more business combinations within 36 months of the effectiveness of its initial public offering registration statement. Since the Company failed to complete its initial business combination by November 4, 2024, the Staff concluded that the Company did not comply with Rule IM-5101-2 and that the Company’s securities are now subject to delisting.공시 • Aug 16Chain Bridge I announced delayed 10-Q filingOn 08/15/2024, Chain Bridge I announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Jul 23Phytanix Bio entered into a definitive business combination agreement to acquire Chain Bridge I (NasdaqCM:CBRG) from Fulton AC 1 LLC and others for $91.9 million in a reverse merger transaction.Phytanix Bio entered into a definitive business combination agreement to acquire Chain Bridge I (NasdaqCM:CBRG) from Fulton AC 1 LLC and others for $91.9 million in a reverse merger transaction on July 22, 2024. Under the terms of the Business Combination Agreement, the aggregate consideration to be paid in the Business Combination is derived from an equity value of $58 million. In addition, HoldCo will issue 17,000 shares of HoldCo Series A convertible preferred stock and issue additional shares of HoldCo preferred stock in exchange for certain short term debt obligations of the Company. HoldCo will also pay an earnout consideration which is, upon the occurrence of Triggering Event I, a one-time issuance of an aggregate of the greater of 5% of the then outstanding fully-diluted common stock and 2,000,000 Earnout Shares; and upon the occurrence of Triggering Event II, a one-time issuance of an aggregate of the greater of 5% of the then outstanding fully-diluted common stock and 1,000,000 Earnout Shares. Upon the closing of the business combination, and assuming no redemptions of shares of CBRG by its public stockholders, Phytanix would expect to receive up to $11 million of cash held in Trust. The business combination is not subject to a minimum cash condition. The parties intend to seek to raise additional convertible preferred stock in the months following the signing of the business combination agreement and will continue to seek to secure such additional financing over time. Upon closing of the transaction, the combined company will be named Phytanix Inc., and its common stock is expected to be listed on the Nasdaq Capital Market under the ticker symbol “PHYX.”. The new company will be led by Phytanix Bio’s founders Colin Stott, the former R&D operations director at GW Pharmaceuticals; Dominic Schiller, who formerly led GW’s external IP strategy for more than a decade; and Barrett Evans, managing director at EMC2 Capital. Mr. Barrett Evans will serve as CEO of the combined company; Mr. Colin Stott will serve as Chief Operating Officer; and Mr. Dominic Schiller will lead the legal and IP strategy. Guy Webber, a former GW preclinical team member and world-leading expert in cannabinoids/drug metabolism, will lead preclinical development for the organization. The Boards of Directors of both Phytanix Bio and CBRG have unanimously approved the proposed transaction, including a separate vote by CBRG’s independent directors. The transaction is expected to be completed in the fourth quarter of 2024, pending approval from both CBRG and Phytanix Bio shareholders, the effectiveness of the Registration Statement to be filed by HoldCo, HoldCo having at least $5,000,001 of net tangible assets, the approval by Nasdaq of HoldCo’s initial listing application in connection with the Business Combination, entry into employment agreements with certain key Company executives and entry into an agreement providing for a $100 million equity line of credit with Keystone Capital Partners, LLC or its affiliates. Nelson Mullins Riley & Scarborough is acting as legal counsel to CBRG. Titan Advisors has acted as capital markets advisors for Phytanix Bio, and Catherine Evans of Law Offices of Catherine Basinger Evans acted as legal advisor for Phytanix Bio.공시 • Jun 27Chain Bridge I Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock MarketOn June 20, 2024, Chain Bridge I received written notice from the Listing Qualifications Department of The Nasdaq Stock Market indicating that the Company no longer complies with the Nasdaq Capital Market continued listing criteria set in Listing Rule 5550(a)(3), which requires the Company to maintain a minimum of 300 public holders. The Notice additionally indicates that the Company, pursuant to the Listing Rules, has 45 calendar days, or until August 5, 2024, to submit a plan to regain compliance. If Nasdaq accepts the Company's plan, the Company will have 180 calendar days from the date of the Notice to evidence compliance. If Nasdaq were to reject the Company’s plan, Nasdaq rules permit the Company to appeal the decision to a hearings panel. The Notice serves only as a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securities on the Nasdaq Capital Market. While the Company can provide no assurances as to timing, the Company intends to take action to submit a plan to regain compliance within the 45 calendar day submission period, and, if Nasdaq accepts the plan to regain compliance, to subsequently regain compliance with Rule 5550(a)(3) within the 180 calendar day compliance period. While the Company is exercising diligent efforts to maintain the listing of its securities on the Nasdaq Capital Market, there can be no assurance that the Company will be able to regain or maintain compliance with the Nasdaq Capital Market minimum number of public holders requirement. In addition, if the Company does not meet the minimum number of public holders requirement by the end of the 180 calendar day compliance period, Nasdaq could provide notice that the Company’s securities will become subject to delisting. In the event the Company receives notice that its securities are being delisted, Nasdaq rules permit the Company to appeal any delisting determination by Nasdaq staff to a hearings panel.공시 • Jan 07Chain Bridge I Appoints Andrew Cohen as Chief Executive OfficerChain Bridge I appointed Andrew Cohen as Chief Executive Officer of the Company.공시 • Jan 06Chain Bridge I Appoints Andrew Cohen, Daniel Wainstein, Lewis Silberman and Paul Baron to the BoardChain Bridge I the Board appointed Andrew Cohen, Daniel Wainstein, Lewis Silberman and Paul Baron to fill the vacancies on the Board created by resignations.공시 • Oct 20Chain Bridge I Appoints David G. Brown as Director and Member of the Audit Committee and Nominating CommitteeOn October 13, 2022, Chain Bridge I announced that David G. Brown has been appointed as a director of the company and a member of the company’s audit committee and nominating committee. Mr. Brown will serve in the class of directors whose term expires at the company’s second general annual meeting of shareholders.공시 • Aug 06Chain Bridge I Announces Resignation of Nathaniel Fick from the Board of Directors and as a Member of its Audit Committee, Compensation Committee and Nominating CommitteeOn August 1, 2022, Nathaniel Fick resigned from the Board of Directors of Chain Bridge I (the “Company”), and as a member of the Company’s Audit Committee, Compensation Committee and Nominating Committee, effective immediately because Mr. Fick has been nominated to serve as the United States Department of State’s Ambassador at Large for Cybersecurity and Digital Policy.매출 및 비용 세부 내역Chain Bridge I가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:CBGG.F 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비30 Sep 24022030 Jun 24012031 Mar 24042031 Dec 23081030 Sep 23062030 Jun 230102031 Mar 230111031 Dec 220111030 Sep 220141030 Jun 220111031 Mar 220810양질의 수익: CBGG.F는 $1.4M 규모의 큰 일회성 이익이 있어 30th September, 2024까지 지난 12개월 재무 결과에 영향을 미쳤습니다.이익 마진 증가: 지난 1년 동안 CBGG.F의 이익률이 개선되었는지 판단하기에 데이터가 부족합니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 지난 5년 동안 CBGG.F의 연간 수익 성장률이 양(+)이었는지 판단하기에 데이터가 부족합니다.성장 가속화: CBGG.F은 지난 1년 동안 수익이 감소하여 5년 평균과 비교할 수 없습니다.수익 대 산업: CBGG.F은 지난 1년 동안 수익이 감소(-62.7%)하여 Capital Markets 업계 평균(38.4%)과 비교하기 어렵습니다.자기자본이익률높은 ROE: CBGG.F의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YDiversified-financials 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/05/27 07:08종가2025/02/27 00:00수익2024/09/30연간 수익2023/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Chain Bridge I는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Apr 02Chain Bridge I announced delayed annual 10-K filingOn 04/01/2026, Chain Bridge I announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Feb 19Chain Bridge I Receives Notice of OTCQB Delisting and Transfer to OTCID Basic MarketAs previously disclosed, on November 12, 2025, Chain Bridge I (the “Company”) received a written notice from the OTC Markets Group (“OTC”) notifying the Company that, because the Company’s public float as it is currently displayed on the Company profile is less than 10% of the total shares outstanding, the Company is not currently in compliance with the public float requirement for continued listing on OTCQB Venture Market (“OTCQB”), as set forth in Section 2 of the OTCQB listing. On February 11, 2026, the Company received a written notice from OTC indicating that the cure period has now expired. Consequently, the Company’s securities were moved from the OTCQB market to the OTCID Basic Market (“OTCID”) on February 12, 2026. OTC further notified the Company that if it would like to be moved back to OTCQB, it must increase public float to at least 10% of the total shares outstanding and meet all of the eligibility requirements under Section 1 of the OTCQB listing standards. The Company will continue to file its periodic reports and remain subject to the reporting obligations under the Securities Exchange Act of 1934. The Company is actively evaluating strategic options to regain compliance with relevant listing standards and remains committed to upholding transparency and stability for all stakeholders.
공시 • Sep 09CommLoan, Inc signed a letter of intent to acquire .Chain Bridge I (OTCPK:CBRR.F) in a reverse merger transaction on September 8, 2025.CommLoan, Inc signed a letter of intent to acquire .Chain Bridge I (OTCPK:CBRR.F) in a reverse merger transaction on September 8, 2025. Under the terms of the LOI, CBRRF and CommLoan would become a combined entity, with CommLoan’s existing equity holders rolling 100% of their equity into the combined public company. Upon the closing of the transaction, the combined company will be named CommLoan Inc., and would be led by CommLoan’s founder and CEO, Mitch Ginsberg. The new company’s common stock is expected to be listed on the Nasdaq Capital Market. CBRRF expects to announce additional details regarding the proposed business combination when a definitive agreement is executed, which is expected later in Q4 2025. The transaction is subject to approval by regulatory board, approval of merger agreement by target board, approval of offer by acquirer shareholders, approval of offer by acquirer board, approval of offer by target shareholders, consummation of due diligence investigation and definitive agreement. The expected completion of the transaction is in first half of 2026.
공시 • Jun 22Chain Bridge I Auditor Raises 'Going Concern' DoubtChain Bridge I filed its Annual on Jun 20, 2025 for the period ending Dec 31, 2024. In this report its auditor, Russell Bedford Stefanou Mirchandani LLP - RBSM LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
공시 • Apr 02Chain Bridge I announced delayed annual 10-K filingOn 04/01/2025, Chain Bridge I announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Nov 20Chain Bridge I(OTCPK:CBRR.F) dropped from NASDAQ Composite IndexChain Bridge I has been removed from NASDAQ Composite Index.
공시 • Nov 15Chain Bridge I announced delayed 10-Q filingOn 11/14/2024, Chain Bridge I announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Nov 13Chain Bridge I to be Delisted from The Nasdaq Stock Market Due to Non-Compliance with Listing Rule IM-5101-2On November 12, 2024, Chain Bridge I (the ‘Company’) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market (‘Nasdaq’) stating that, pursuant to Nasdaq Listing Rule IM-5101-2 (‘Rule IM-5101-2’), the staff of Nasdaq (‘Staff’) had determined that (i) the Company’s securities will be delisted from Nasdaq, (ii) trading of the Company’s Class A common stock and units will be suspended at the opening of business on November 19, 2024 and (iii) a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Company’s securities from listing and registration on Nasdaq. Under Rule IM-5101-2, a special purpose acquisition company must complete one or more business combinations within 36 months of the effectiveness of its initial public offering registration statement. Since the Company failed to complete its initial business combination by November 4, 2024, the Staff concluded that the Company did not comply with Rule IM-5101-2 and that the Company’s securities are now subject to delisting.
공시 • Aug 16Chain Bridge I announced delayed 10-Q filingOn 08/15/2024, Chain Bridge I announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Jul 23Phytanix Bio entered into a definitive business combination agreement to acquire Chain Bridge I (NasdaqCM:CBRG) from Fulton AC 1 LLC and others for $91.9 million in a reverse merger transaction.Phytanix Bio entered into a definitive business combination agreement to acquire Chain Bridge I (NasdaqCM:CBRG) from Fulton AC 1 LLC and others for $91.9 million in a reverse merger transaction on July 22, 2024. Under the terms of the Business Combination Agreement, the aggregate consideration to be paid in the Business Combination is derived from an equity value of $58 million. In addition, HoldCo will issue 17,000 shares of HoldCo Series A convertible preferred stock and issue additional shares of HoldCo preferred stock in exchange for certain short term debt obligations of the Company. HoldCo will also pay an earnout consideration which is, upon the occurrence of Triggering Event I, a one-time issuance of an aggregate of the greater of 5% of the then outstanding fully-diluted common stock and 2,000,000 Earnout Shares; and upon the occurrence of Triggering Event II, a one-time issuance of an aggregate of the greater of 5% of the then outstanding fully-diluted common stock and 1,000,000 Earnout Shares. Upon the closing of the business combination, and assuming no redemptions of shares of CBRG by its public stockholders, Phytanix would expect to receive up to $11 million of cash held in Trust. The business combination is not subject to a minimum cash condition. The parties intend to seek to raise additional convertible preferred stock in the months following the signing of the business combination agreement and will continue to seek to secure such additional financing over time. Upon closing of the transaction, the combined company will be named Phytanix Inc., and its common stock is expected to be listed on the Nasdaq Capital Market under the ticker symbol “PHYX.”. The new company will be led by Phytanix Bio’s founders Colin Stott, the former R&D operations director at GW Pharmaceuticals; Dominic Schiller, who formerly led GW’s external IP strategy for more than a decade; and Barrett Evans, managing director at EMC2 Capital. Mr. Barrett Evans will serve as CEO of the combined company; Mr. Colin Stott will serve as Chief Operating Officer; and Mr. Dominic Schiller will lead the legal and IP strategy. Guy Webber, a former GW preclinical team member and world-leading expert in cannabinoids/drug metabolism, will lead preclinical development for the organization. The Boards of Directors of both Phytanix Bio and CBRG have unanimously approved the proposed transaction, including a separate vote by CBRG’s independent directors. The transaction is expected to be completed in the fourth quarter of 2024, pending approval from both CBRG and Phytanix Bio shareholders, the effectiveness of the Registration Statement to be filed by HoldCo, HoldCo having at least $5,000,001 of net tangible assets, the approval by Nasdaq of HoldCo’s initial listing application in connection with the Business Combination, entry into employment agreements with certain key Company executives and entry into an agreement providing for a $100 million equity line of credit with Keystone Capital Partners, LLC or its affiliates. Nelson Mullins Riley & Scarborough is acting as legal counsel to CBRG. Titan Advisors has acted as capital markets advisors for Phytanix Bio, and Catherine Evans of Law Offices of Catherine Basinger Evans acted as legal advisor for Phytanix Bio.
공시 • Jun 27Chain Bridge I Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock MarketOn June 20, 2024, Chain Bridge I received written notice from the Listing Qualifications Department of The Nasdaq Stock Market indicating that the Company no longer complies with the Nasdaq Capital Market continued listing criteria set in Listing Rule 5550(a)(3), which requires the Company to maintain a minimum of 300 public holders. The Notice additionally indicates that the Company, pursuant to the Listing Rules, has 45 calendar days, or until August 5, 2024, to submit a plan to regain compliance. If Nasdaq accepts the Company's plan, the Company will have 180 calendar days from the date of the Notice to evidence compliance. If Nasdaq were to reject the Company’s plan, Nasdaq rules permit the Company to appeal the decision to a hearings panel. The Notice serves only as a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securities on the Nasdaq Capital Market. While the Company can provide no assurances as to timing, the Company intends to take action to submit a plan to regain compliance within the 45 calendar day submission period, and, if Nasdaq accepts the plan to regain compliance, to subsequently regain compliance with Rule 5550(a)(3) within the 180 calendar day compliance period. While the Company is exercising diligent efforts to maintain the listing of its securities on the Nasdaq Capital Market, there can be no assurance that the Company will be able to regain or maintain compliance with the Nasdaq Capital Market minimum number of public holders requirement. In addition, if the Company does not meet the minimum number of public holders requirement by the end of the 180 calendar day compliance period, Nasdaq could provide notice that the Company’s securities will become subject to delisting. In the event the Company receives notice that its securities are being delisted, Nasdaq rules permit the Company to appeal any delisting determination by Nasdaq staff to a hearings panel.
공시 • Jan 07Chain Bridge I Appoints Andrew Cohen as Chief Executive OfficerChain Bridge I appointed Andrew Cohen as Chief Executive Officer of the Company.
공시 • Jan 06Chain Bridge I Appoints Andrew Cohen, Daniel Wainstein, Lewis Silberman and Paul Baron to the BoardChain Bridge I the Board appointed Andrew Cohen, Daniel Wainstein, Lewis Silberman and Paul Baron to fill the vacancies on the Board created by resignations.
공시 • Oct 20Chain Bridge I Appoints David G. Brown as Director and Member of the Audit Committee and Nominating CommitteeOn October 13, 2022, Chain Bridge I announced that David G. Brown has been appointed as a director of the company and a member of the company’s audit committee and nominating committee. Mr. Brown will serve in the class of directors whose term expires at the company’s second general annual meeting of shareholders.
공시 • Aug 06Chain Bridge I Announces Resignation of Nathaniel Fick from the Board of Directors and as a Member of its Audit Committee, Compensation Committee and Nominating CommitteeOn August 1, 2022, Nathaniel Fick resigned from the Board of Directors of Chain Bridge I (the “Company”), and as a member of the Company’s Audit Committee, Compensation Committee and Nominating Committee, effective immediately because Mr. Fick has been nominated to serve as the United States Department of State’s Ambassador at Large for Cybersecurity and Digital Policy.